Compare Natera Inc. Common Stock (NTRA) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Wix.Com Ltd — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Wix.Com Ltd trades at $74 (market cap $3.00B). The key difference: Natera Inc. Common Stock is far larger — about 19× Wix.Com Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Wix.Com Ltd for 62 Days on average.
| NTRA | WIX | |
|---|---|---|
Market Cap | $57.03B | $3.00B |
Volume | 1,131,157 | 960,938 |
Sector | Health | Technology |
52-Week High | $425.64 | $145.54 |
52-Week Low | $179.42 | $40.43 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $56.18B | $4.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
WIX trades at $74.31, up 0.18% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue growth is strong, reaching $1.99B in 2025, though net income margin turned negative at -8.19% in 2026. The company faces multiple class-action lawsuits filed in September 2026, adding legal overhangs. Analyst consensus remains bullish with a $77.00 price target, but negative equity and volatile cash flows highlight financial instability.
The outlook is mixed: robust revenue growth and analyst support offer upside, but profitability challenges, negative equity, and legal risks pose significant headwinds. Investors should weigh the high P/E of 62.84 against earnings volatility and litigation uncertainties before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
